Tamoxifen Not Helpful In Estrogen Receptor-Negative Tumors
NEW ORLEANS, LA -- May 25, 2000 -- Hormonal therapy with tamoxifen, commonly used for the treatment of breast cancer, is not helpful in women who have tumors that are estrogen-receptor negative, and whose cancers have not yet spread to the lymph nodes.
The news, released here at the 36th annual meeting of the American Society of Clinical Oncology, is based on a major study of 2,008 women with estrogen receptor-negative, node-negative disease breast cancer.
The study also found that after surgical removal of the tumor, the women did equally well on either of the two most-common adjuvant chemotherapy regimens, adriamycin-cyclophosphamide (AC) or cyclophosphamide-methotrexate-fluorouracil (CMF).
Bernard Fisher, MD, of the National Surgical Adjuvant Breast and Bowel Project, in Pittsburgh, said there has been a controversy over the past decade about tamoxifen's use in these patients, due to differing trial results in Europe and North America and speculation that tamoxifen does not act strictly at the estrogen-receptor site.
He said the question about AC versus CMF was over efficacy as well as side effect profiles. Also, the AC regimen is given in a much shorter time, 63 days, versus six months for CMF.
In Dr. Fisher's study, 2,008 women received AC or CMF, with-or-without tamoxifen. The percentage of women without disease at five years was 82 percent in both treatment groups, and with-or-without tamoxifen.
"The results indicate there is no benefit from the use of tamoxifen in estrogen-receptor negative, node-negative patients, whether they receive AC or CMF," Dr. Fisher stated. "Also, there was no difference in outcome whether the women received AC or CMF."
He concluded that there is no justification for giving tamoxifen to estrogen-negative, node-negative patients, and there is no difference between the two major chemotherapy combinations.
Although there could be advantages to taking the AC regimen, due to the shorter length of treatment, Dr. Fisher advised that women who were already taking CMF chemotherapy continue with that regimen rather than being switched.
By Robert H. Carlson
Special to DG News
Ann's NOTE: Anyone offered AC regimen MUST ask what the overall survival benefit is. This is a question to ask when presented with ANY treatment options. To suggest that AC be taken because it is "shorter" is SO crazy! AC is cardio-toxic meaning it CAN cause damage to the heart. It is a very difficult regimen to go through. I think Dr. Fisher forgot about Quality of Life.
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.